in parallel to the tube axis, a large dipole will be generated
in the PNTs, which may have a potential application to
molecular devices. However, PNTs generally possess low
electronic conductivity,8 which may restrict their application.
To improve the electronic conductivity of PNTs, incorpora-
tion of π-systems and/or metal ions to the PNT may be
effective. Therefore, the PNT bearing the π-systems with
the ability to form a metal complex was prepared in this
work. 2,2′:6′,2′′-Terpyridine (tpy) was chosen as the ligand.
Tpy is one of the most versatile building blocks in supramo-
lecular chemistry as demonstrated by Lehn et al.9 This
tridentate ligand is able to form complexes with various
transition metal ions with high binding constants.10 The
present paper reports on the molecular assembly formation
and metal binding property of cyclic tri-â-peptide having
tpy ligands at the side chains.
Scheme 1. Synthetic Route of Cyclo[â-Glu(tpy)3]a
Peptide Design and Synthesis. Metal ions such as Ru-
(II) and Fe(II) form complexes with tpy ligands preferably
taking six-coordinate geometry. In the present study, this
geometry will put a severe constraint on a tubular structure
of stacking cyclic tri-â-peptides when two tpy ligands of
adjacent cyclic peptides in the tube are forced to accom-
modate the metal ion. We therefore selected Cu(II), which
prefers four- or five-coordinate geometry with one tpy
ligand.11 The long piperadine spacer was inserted between
the cyclic skeleton and the tpy ligand in the molecule to avoid
steric hindrance and electrostatic repulsion between the
neighboring ligands either in free or complex form. When
these two factors are avoided, the cyclic tri-â-peptide will
take a planar structure including the side chain keeping the
regular PNT structure even after complexation. The cyclic
tri-â-peptide having three tpy ligands was prepared by a
liquid-phase method (Scheme 1). Boc-[â-Glu(OBzl)]-OtBu
and Boc-[â-Glu(OBzl)]-Opac were synthesized from [â-Glu-
(OBzl)]-OH. Chain extension reactions to the linear di- and
tripeptides were carried out using HATU as a coupling
reagent. In the case of the synthesis of the trimer, the Boc
group of Boc-[â-Glu(OBzl)]-OtBu was selectively removed
without cleavage of tert-butoxy ester by 4 N HCl-dioxane
according to the previous report.12 After the chemical
conversion from benzyl ester to the tpy derivative at the side
chain and removal of the protecting groups at the both
terminals of the main chain with treatment of TFA, cycliza-
tion reaction was carried out using HATU, HOAT and DIEA
a Abbreviations: DMAP, N,N-dimethylaminopyridine; HATU,
O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium haxafluo-
rophosphate; DIEA, N,N-diisopropylethylamine; HOAT, 1-hydroxy-
7-azabenzotriazole; tpy-NH, 4′-(2-piperidin-4-yloxy)-2,2′:6′,2′′-
terpyridine.
(H-N-Câ-Hâ) of 172° according to the Karplus equation.13
The dihedral angle indicates the anti relationship between
the NH and Hâ, which is similar to the result of the other
cyclic tri-â-peptide.6,14
Assembly Formation. The trimer showed high solubility
for a variety of mixed solutions of polar and nonpolar
solvents such as CHCl3-MeOH, THF-CH3CN, and even
THF-H2O.15 This unprecedented solubility of the cyclic tri-
â-peptide may be ascribed to high solubility of tpy ligands
and the difficulty in formation of intermolecular hydrogen
bonds to grow into a tubular structure probably due to the
introduction of the bulky tpy ligands at the side chains.
However, we succeeded in preparing a straight needle-like
assembly under a proper assembling condition. Figure 1
shows the crystals of cyclo[â-Glu(tpy)3] which were recrys-
tallized from THF-CH3CN. When the crystals were ob-
1
in DMF (0.1 mM). H NMR spectrum of the trimer in
DMSO-d6 clearly indicates that the predominant conforma-
tion is C3 symmetric on a NMR time scale. The spin coupling
constants between amide proton and Hâ in the cyclic skeleton
was found to be 9.0 Hz, which gives the dihedral angle of θ
(8) (a) Okamoto, H.; Nakanishi, T.; Nagai, Y.; Kasahara, M.; Takeda,
K. J. Am. Chem. Soc. 2003, 125, 2756. (b) Ashkenasy, N.; Horne, W. S.;
Ghadiri, M. R. Small 2006, 2, 99.
(9) (a) Lehn, J. M. Supramolecular Chemistry, Concepts and Perspec-
tiVes; VCH: Weinheim, 1995. (b) Lehn, J. M. Angew. Chem., Int. Ed. 1988,
27, 89. (c) Schubert, U. S.; Eschbaumer, C. Angew. Chem., Int. Ed. 2002,
41, 2893.
(10) Dobrawa, R.; Lysetska, M.; Ballester, P.; Grune, M.; Wurthner, F.
Macromolecules 2005, 38, 1315.
(11) Cardenas, D. J.; Livoreil, A.; Sauvage, J. P. J. Am. Chem. Soc. 1996,
118, 11980.
(13) Karplus, M. J. Chem. Phys. 1959, 30, 11.
(14) Fujimura, F.; Hirata, T.; Morita, T.; Kimura, S.; Horikawa, Y.;
Sugiyama, J. Biomacromolecules 2006, 7, 2394.
(15) General cyclic â-peptides have a severe solubility problem: (a)
Gademann, K.; Seebach, D. HelV. Chim. Acta 1999, 82, 957. (b) Matthews,
J. L.; Overhand, M.; Kuhnle, F. N. M.; Ciceri, P. E.; Seebach, D. Liebigs
Ann. 1997, 1371.
(12) Han, G.; Tamaki, M.; Hruby, V. J. Peptide Res. 2001, 58, 338.
794
Org. Lett., Vol. 9, No. 5, 2007